<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alyssa R Letourneau, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Hooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Beta-lactam antibiotics are among the most commonly prescribed drugs, grouped together based upon a shared structural feature, the beta-lactam ring. The classification, spectrum of activity and pharmacology of one group of beta-lactam antibiotics, the penicillins, will be reviewed here. The mechanisms of action and resistance and major adverse reactions of the beta-lactam antibiotics are discussed separately (see  <a class="medical medical_review" href="/d/html/479.html" rel="external">"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects"</a>). The cephalosporins and other beta-lactam drugs are also discussed separately. (See  <a class="medical medical_review" href="/d/html/480.html" rel="external">"Cephalosporins"</a> and  <a class="medical medical_review" href="/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams"</a>.) </p><p class="headingAnchor" id="H2"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Penicillins can be classified into the following categories:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">Penicillin G</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antistaphylococcal penicillins (<a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">nafcillin</a>, <a class="drug drug_general" data-topicid="9724" href="/d/drug information/9724.html" rel="external">oxacillin</a>, <a class="drug drug_general" data-topicid="9288" href="/d/drug information/9288.html" rel="external">cloxacillin</a> and <a class="drug drug_general" data-topicid="9349" href="/d/drug information/9349.html" rel="external">dicloxacillin</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Broad-spectrum penicillins: second generation (<a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> and related agents), third generation (carbenicillin and ticarcillin) and fourth generation (<a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a>)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">SPECTRUM OF ACTIVITY</span><span class="headingEndMark"> — </span>One of the major differences among the penicillins is the range of bacteria against which they are active.</p><p class="headingAnchor" id="H4"><span class="h2">Penicillin G</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">Penicillin G</a> is highly active against:</p><p class="bulletIndent1"><span class="glyph">●</span>Gram-positive cocci (except penicillinase-producing staphylococci, penicillin-resistant pneumococci [<a href="#rid1">1-5</a>], some enterococci, and oxacillin-resistant staphylococci) (see  <a class="medical medical_review" href="/d/html/7034.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to beta-lactam antibiotics"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gram-positive rods such as <em>Listeria</em></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gram-negative cocci such as <em>Neisseria</em> spp (except penicillinase-producing <em>Neisseria</em>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most anaerobes (with certain important exceptions, including <em>Bacteroides</em>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spirochetes</p><p></p><p><a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">Penicillin G</a> is only bacteriostatic for enterococci; reports document strains with increasing intrinsic resistance to penicillin and, rarely, with high level resistance due to penicillinase production [<a href="#rid6">6</a>] (see  <a class="medical medical_review" href="/d/html/470.html" rel="external">"Mechanisms of antibiotic resistance in enterococci"</a>). Serious infections with enterococci are generally treated with combination therapy of a cell wall active antibiotic such as penicillin, <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, or <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> plus <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> or <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> (unless high level resistance to these aminoglycosides is present). Penicillin G is not active against gram-negative bacilli because of poor penetration through the porin channel. (See  <a class="medical medical_review" href="/d/html/479.html" rel="external">"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects", section on 'Mechanisms of bacterial resistance'</a>.)</p><p>Parenteral penicillin is the treatment of choice for <em>Treponema pallidum</em> (syphilis); there have been no reports of resistance to penicillin despite its use over decades (see  <a class="medical medical_review" href="/d/html/7597.html" rel="external">"Syphilis: Treatment and monitoring"</a>). Penicillin is also active against <em>Borrelia </em>species, including <em>Borrelia burgdorferi</em>,<em> </em>which causes Lyme disease, and against <em>Leptospira </em>species. (See  <a class="medical medical_review" href="/d/html/7896.html" rel="external">"Treatment of Lyme disease"</a> and  <a class="medical medical_review" href="/d/html/5524.html" rel="external">"Leptospirosis: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Antistaphylococcal penicillins</span><span class="headingEndMark"> — </span>Antistaphylococcal penicillins (<a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">nafcillin</a>, <a class="drug drug_general" data-topicid="9724" href="/d/drug information/9724.html" rel="external">oxacillin</a>, <a class="drug drug_general" data-topicid="9288" href="/d/drug information/9288.html" rel="external">cloxacillin</a> and <a class="drug drug_general" data-topicid="9349" href="/d/drug information/9349.html" rel="external">dicloxacillin</a>) inhibit penicillinase-producing staphylococci but are inactive against oxacillin-resistant staphylococci [<a href="#rid7">7</a>] (see  <a class="medical medical_review" href="/d/html/3153.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA): Microbiology"</a>). However, for strains of <em>Staphylococcus aureus</em> sensitive to oxacillin, antistaphylococcal penicillins or <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a> are preferable to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> because vancomycin is less active against <em>S. aureus</em> than beta-lactams in in vitro and clinical studies [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Methicillin-sensitive S. aureus'</a>.)</p><p>Antistaphylococcal penicillins have less intrinsic activity than <a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">penicillin G</a> for bacteria susceptible to both, and antistaphylococcal penicillins are ineffective for enterococci, <em>Listeria</em>, and <em>Neisseria</em> spp.</p><p class="headingAnchor" id="H6"><span class="h2">Broad-spectrum penicillins</span><span class="headingEndMark"> — </span>The broad-spectrum penicillins are distinguished by their activity against gram-negative bacilli. These agents have been stratified into the second-generation penicillins (<a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> and related agents), the third-generation penicillins (carbenicillin and ticarcillin), and the fourth-generation penicillin <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a>. None of the broad-spectrum penicillins are effective against penicillinase-producing staphylococci.</p><p class="headingAnchor" id="H7"><span class="h3">Second generation</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">Ampicillin</a>, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, and closely related antibiotics are able to penetrate the porin channel of gram-negative bacteria but are not stable to beta-lactamases. These antibiotics are active against the majority of strains of <em>Escherichia coli</em>, <em>Proteus mirabilis</em>, <em>Salmonella</em>, <em>Shigella</em>, and <em>Haemophilus influenzae</em>. While a large percentage of encapsulated <em>H. influenzae</em> type b from the blood and cerebrospinal fluid (CSF) of children are beta-lactamase positive (and ampicillin resistant), a much lower percent of the non-type b isolates from adult patients with community-acquired pneumonia are beta-lactamase positive [<a href="#rid9">9-13</a>].</p><p><a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">Amoxicillin</a> can also be used for spirochetal disease including as an alternative therapy for syphilis (combined with <a class="drug drug_general" data-topicid="9812" href="/d/drug information/9812.html" rel="external">probenecid</a>), Lyme disease, relapsing fever syndromes due to <em>Borrelia </em>species, and selected patients with leptospirosis. (See  <a class="medical medical_review" href="/d/html/7597.html" rel="external">"Syphilis: Treatment and monitoring"</a> and  <a class="medical medical_review" href="/d/html/7896.html" rel="external">"Treatment of Lyme disease"</a> and  <a class="medical medical_review" href="/d/html/5524.html" rel="external">"Leptospirosis: Treatment and prevention"</a>.)</p><p><a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">Amoxicillin</a> is also as part of combination therapy for <em>Helicobacter pylori</em>. (See  <a class="medical medical_review" href="/d/html/7.html" rel="external">"Treatment regimens for Helicobacter pylori in adults"</a>.)</p><p><a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">Amoxicillin</a> and <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> have an identical spectrum of activity, but amoxicillin is better absorbed from the intestine when administered orally and yields higher blood and urine levels. Amoxicillin is available generically and is preferable to ampicillin for oral use except in the therapy of <em>Shigella</em> infections sensitive to ampicillin. (See  <a class="medical medical_review" href="/d/html/2701.html" rel="external">"Shigella infection: Treatment and prevention in adults"</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Third generation</span><span class="headingEndMark"> — </span>Carbenicillin and ticarcillin also can penetrate the porin channel of gram-negative bacteria in high doses but are less active than <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> on a weight basis. However, the carboxy group on the side chain of these antibiotics expands the spectrum of activity by rendering them more resistant to the chromosomal beta-lactamases of certain organisms, such as indole-positive <em>Proteus</em> species, <em>Enterobacter</em> species, and <em>Pseudomonas</em> <em>aeruginosa</em>. Third and fourth generation penicillins are most useful in infections caused by these organisms.</p><p>Carbenicillin indanyl sodium is an orally absorbed form of carbenicillin which may be indicated for oral therapy of resistant urinary tract infections. Oral carbenicillin is not effective for therapy of infections outside of the urinary tract. Carbenicillin is not available in the United States and of limited availability globally.</p><p>Ticarcillin has the same spectrum of activity as carbenicillin but is two to four times more active on a weight basis against <em>P. aeruginosa</em>. Ticarcillin is a disodium salt (which may cause a problem in patients with volume overload) and may cause a bleeding diathesis by inhibition of platelet function and prolongation of the bleeding time. Ticarcillin (single-ingredient) and ticarcillin-clavulanate (combination with a beta-lactamase inhibitor) are not available in the United States and are of limited availability globally. (See  <a class="medical medical_review" href="/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Beta-lactamase inhibitor combinations'</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Fourth generation</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">Piperacillin</a> is a derivative of <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> [<a href="#rid14">14</a>]. It covers much the same spectrum as carbenicillin and ticarcillin but is more active in vitro on a weight basis. In addition, it has some activity against strains of <em>Klebsiella</em>, although cephalosporins remain the preferred agents. It is more active than carbenicillin or ticarcillin against enterococci and <em>Bacteroides fragilis</em>, but other agents are preferred for the treatment of these organisms as well.</p><p><a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">Piperacillin</a> is somewhat more active against <em>Enterobacterales</em> than carbenicillin or ticarcillin and more active than ticarcillin against <em>P. aeruginosa</em>. As with ticarcillin, clinical failures have occurred when piperacillin is used as a single agent to treat serious <em>Pseudomonas</em> infections. Piperacillin is usually administered now in combination with a beta-lactamase inhibitor. (See  <a class="medical medical_review" href="/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Beta-lactamase inhibitor combinations'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">PHARMACOLOGY</span><span class="headingEndMark"> — </span>The half-lives of the penicillins are similar and all achieve adequate levels in most bodily fluids, but dose adjustment with renal insufficiency depends upon the presence of nonrenal routes of excretion and differs among these drugs.</p><p class="headingAnchor" id="H11"><span class="h2">Half-life</span><span class="headingEndMark"> — </span>All of the available penicillins have relatively short half-lives (generally one hour or less); all of the parenteral agents are usually administered on an every-four-hour basis when treating serious systemic infections in patients with normal renal function. <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">Piperacillin</a> has dose-dependent pharmacokinetics and a longer half-life when higher doses are administered.</p><p class="headingAnchor" id="H12"><span class="h2">Levels in different bodily fluids</span><span class="headingEndMark"> — </span>All of the penicillins achieve therapeutic levels in pleural, pericardial, peritoneal and synovial fluids, as well as urine. All achieve levels in bile higher than corresponding serum levels (assuming the absence of obstruction); <a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">nafcillin</a>, <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, and <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a> achieve very high levels in bile.</p><p>The penicillins penetrate the CSF poorly in the absence of inflammation but achieve therapeutic levels in patients with meningitis who are given meningeal doses of parenteral therapy  (<a class="graphic graphic_table graphicRef51256" href="/d/graphic/51256.html" rel="external">table 1</a>). </p><p class="headingAnchor" id="H13"><span class="h2">Dose adjustment with kidney insufficiency</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">Nafcillin</a>, <a class="drug drug_general" data-topicid="9724" href="/d/drug information/9724.html" rel="external">oxacillin</a>, <a class="drug drug_general" data-topicid="9288" href="/d/drug information/9288.html" rel="external">cloxacillin</a>, and <a class="drug drug_general" data-topicid="9349" href="/d/drug information/9349.html" rel="external">dicloxacillin</a> have major nonrenal routes of clearance and need no dosing modification even in the presence of severe kidney failure. <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">Ampicillin</a> and the structurally related antibiotic <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a> require dose modification predominantly when the creatinine clearance (CrCl) is below 50 or 40 mL/min respectively. </p><p>The dosing of penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins and adjustment of dose in the patient with kidney dysfunction are shown in the table  (<a class="graphic graphic_table graphicRef142581" href="/d/graphic/142581.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H8071173"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Penicillin spectrum of activity</strong> – <a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">Penicillin G</a> is highly active against most gram-positive cocci, gram-positive rods, gram-negative cocci, and anaerobes. Exceptions are bacteria from these classes that have acquired resistance to penicillin as well as certain anaerobes that produce a beta-lactamase such as <em>Bacteroides</em>. Penicillin is only bacteriostatic against enterococci. It is also active against spirochetes. (See <a class="local">'Penicillin G'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antistaphylococcal penicillins</strong> – For strains of <em>S. aureus</em> sensitive to <a class="drug drug_general" data-topicid="9724" href="/d/drug information/9724.html" rel="external">oxacillin</a>, antistaphylococcal penicillins or <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a> are preferable to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> because they are more active in vitro and in clinical studies. (See <a class="local">'Antistaphylococcal penicillins'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Broad-spectrum penicillins</strong> – These include <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> and <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a> and have increased activity over <a class="drug drug_general" data-topicid="9749" href="/d/drug information/9749.html" rel="external">penicillin G</a> against gram-negative bacilli but are variably inactivated by beta-lactamases. (See <a class="local">'Broad-spectrum penicillins'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetics</strong> – All penicillins have relatively short half-lives and require frequent administration when given parenterally. Cerebrospinal fluid (CSF) penetration is poor except in the presence of inflammation. Doses and dose adjustments for kidney impairment are listed in the table  (<a class="graphic graphic_table graphicRef142581" href="/d/graphic/142581.html" rel="external">table 2</a>). (See <a class="local">'Pharmacology'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 1997; 24 Suppl 1:S85.</a></li><li><a class="nounderline abstract_t">Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331:377.</a></li><li><a class="nounderline abstract_t">Bradley JS, Scheld WM. The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Clin Infect Dis 1997; 24 Suppl 2:S213.</a></li><li><a class="nounderline abstract_t">Pallares R, Liñares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474.</a></li><li><a class="nounderline abstract_t">Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917.</a></li><li><a class="nounderline abstract_t">Herman DJ, Gerding DN. Antimicrobial resistance among enterococci. Antimicrob Agents Chemother 1991; 35:1.</a></li><li><a class="nounderline abstract_t">Mulligan ME, Murray-Leisure KA, Ribner BS, et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993; 94:313.</a></li><li><a class="nounderline abstract_t">Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.</a></li><li><a class="nounderline abstract_t">Jorgensen JH, Doern GV, Maher LA, et al. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990; 34:2075.</a></li><li><a class="nounderline abstract_t">Heilmann KP, Rice CL, Miller AL, et al. Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. Antimicrob Agents Chemother 2005; 49:2561.</a></li><li><a class="nounderline abstract_t">Geelen TH, Stassen FR, Hoogkamp-Korstanje JA, et al. Antimicrobial resistance among respiratory Haemophilus influenzae isolates from pulmonology services over a six-year period. Scand J Infect Dis 2013; 45:606.</a></li><li><a class="nounderline abstract_t">Vallejo JG, McNeil JC, Hultén KG, et al. Invasive Haemophilus influenzae Disease at Texas Children's Hospital, 2011 to 2018. Pediatr Infect Dis J 2019; 38:900.</a></li><li><a class="nounderline abstract_t">Ieven M, Coenen S, Loens K, et al. Aetiology of lower respiratory tract infection in adults in primary care: a prospective study in 11 European countries. Clin Microbiol Infect 2018; 24:1158.</a></li><li><a class="nounderline abstract_t">Bush LM, Johnson CC. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. Infect Dis Clin North Am 2000; 14:409.</a></li></ol></div><div id="topicVersionRevision">Topic 473 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8994784" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Antibiotic resistance in Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8028618" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9126696" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7623879" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136262" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1901693" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antimicrobial resistance among enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8452155" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709046" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2127342" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15917574" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23746341" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Antimicrobial resistance among respiratory Haemophilus influenzae isolates from pulmonology services over a six-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31107422" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Invasive Haemophilus influenzae Disease at Texas Children's Hospital, 2011 to 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29447989" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Aetiology of lower respiratory tract infection in adults in primary care: a prospective study in 11 European countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10829263" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
